< Go Back
WHO TO TREAT
Prostate cancer biopsies are challenging. Often doctors suspect there is cancer but the biopsy is negative and the doctor and patient wonder if the cancer was simply missed. These tests help to determine who should undergo a repeat biopsy and in the case of ConfirmMDx also let doctors know where to focus the repeat biopsy if it is needed.
ProMark
ProMark is an advanced prognostic test developed specifically for prostate cancer. If you have a biopsy Gleason score 3+3 or 3+4, ProMark uses automated image recognition technology to predict risk of having an aggressive prostate cancer.
Oncotype DX AR-V7
Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next step.
Prolaris
Prolaris is a measure of how fast a prostate cancer tumor is growing. Biopsy tissue samples can be used to determine a patient’s personal Prolaris Score. Studies have shown that Prolaris provides an accurate assessment of cancer aggressiveness.
Oncotype DX GPS
The Oncotype DX Gemonic Prostate Score harnesses the power of genomics to provide a more precise and accurate assessment of risk based on individual tumor biology.
Decipher
The Decipher Prostate RP test predicts the probability of metastasis after surgery and provides an independent assessment of tumor aggressiveness; information distinct from that provided by Gleason score or PSA.
